Congress recently made a number of changes to Medicare's "Part D" prescription drug benefit. The changes were part of President Joe Biden's signature legislation, the Inflation Reduction Act. The legi ...
The U.S. pharmaceutical industry is attempting to delay the timeline for Medicare's drug price negotiations following the ...
Congress recently made a number of changes to Medicare’s “Part D” prescription drug benefit. The changes were part of ...
The Medicare Annual Election Period (AEP) is a critical time for beneficiaries to review and update their coverage. In a ...
The Biden administration's proposed rule could expand coverage of anti-obesity medications for Medicare and Medicaid ...
With fewer Part D plans and a $2,000 out-of-pocket cap, beneficiaries must rethink their Medicare drug coverage for 2025.
The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest ...
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions ...
President Joe Biden has proposed expanding Medicare and Medicaid coverage to include anti-obesity drugs, potentially lowering ...
Big changes are coming to Medicare in 2025, and they could make a major difference in your prescription drug costs. Thanks to the Inflation Reduction Act, Medicare beneficiaries will see the most ...
While recent advances in medicine have created prescription anti-obesity GLP-1 medications — like Ozempic, Wegovy, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback